Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 63.76M | 57.80M | 176.23M | 111.30M | 110.70M | 118.19M |
Gross Profit | 61.18M | 57.80M | -45.33M | 99.19M | 101.26M | -62.45M |
EBITDA | -72.14M | -89.09M | -87.43M | -189.17M | -173.90M | -123.87M |
Net Income | -79.45M | -97.94M | -257.83M | -192.28M | -178.30M | -121.12M |
Balance Sheet | ||||||
Total Assets | 86.17M | 101.64M | 165.32M | 562.51M | 721.92M | 938.55M |
Cash, Cash Equivalents and Short-Term Investments | 25.18M | 41.92M | 81.00M | 277.63M | 464.72M | 691.95M |
Total Debt | 24.88M | 30.57M | 38.10M | 43.11M | 48.08M | 42.09M |
Total Liabilities | 81.26M | 78.86M | 82.43M | 267.55M | 346.58M | 441.18M |
Stockholders Equity | 4.91M | 22.77M | 82.89M | 294.96M | 375.34M | 497.37M |
Cash Flow | ||||||
Free Cash Flow | -44.89M | -67.41M | -246.00M | -243.80M | -256.53M | 155.16M |
Operating Cash Flow | -44.63M | -67.14M | -224.84M | -223.63M | -233.25M | 169.88M |
Investing Cash Flow | 1.68M | 37.52M | 153.53M | 59.28M | 248.20M | -271.63M |
Financing Cash Flow | 14.39M | 28.38M | 14.59M | 84.66M | 32.86M | 153.10M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $196.42M | ― | -32.97% | ― | ― | ― | |
47 Neutral | $129.30M | ― | -262.12% | ― | 239.92% | 79.41% | |
46 Neutral | $137.53M | ― | -79.02% | ― | -100.00% | 38.72% | |
46 Neutral | C$194.28M | -4.22 | -8.60% | 2.64% | 13.54% | -1.44% | |
45 Neutral | $377.30M | ― | -32.12% | ― | ― | 10.98% | |
38 Underperform | $317.07M | ― | -66.13% | ― | ― | 43.21% | |
30 Underperform | $125.58M | ― | -744.59% | ― | ― | 27.65% |
On June 24, 2025, Sangamo Therapeutics, Inc. announced positive topline results from its Phase 1/2 STAAR study of isaralgagene civaparvovec, a gene therapy for Fabry disease. The study showed significant improvements in kidney function and quality of life measures, with a favorable safety profile. These results support the potential of isaralgagene civaparvovec as a one-time treatment for Fabry disease, paving the way for a Biologics Licensing Application under the Accelerated Approval pathway by early 2026.
The most recent analyst rating on (SGMO) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.
On June 12, 2025, Sangamo Therapeutics, Inc. held its annual meeting where stockholders approved significant amendments to the 2018 Equity Incentive Plan. This included increasing the number of shares available for issuance and the number of shares for incentive stock options. The meeting also saw the election of directors, approval of executive compensation, and ratification of Ernst & Young LLP as the company’s independent auditor. These decisions reflect Sangamo’s strategic focus on expanding its equity incentives to attract and retain talent, which could enhance its competitive position in the biotech industry.
The most recent analyst rating on (SGMO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.
On May 12, 2025, Sangamo Therapeutics announced an underwriting agreement with Cantor Fitzgerald & Co. for the issuance and sale of shares and warrants, aiming to raise approximately $23 million. This offering, expected to close on May 14, 2025, is part of Sangamo’s strategy to bolster its financial position, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (SGMO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.
On April 30, 2025, Sangamo Therapeutics, Inc. received a deficiency notice from Nasdaq due to its common stock’s bid price closing below $1.00 per share for 30 consecutive business days, which is below the required minimum for continued listing. The company has until October 27, 2025, to regain compliance by maintaining a minimum bid price of $1.00 per share for at least 10 consecutive business days. If compliance is not achieved by then, Sangamo may qualify for an additional 180-day compliance period, provided it meets other listing requirements and notifies Nasdaq of its intention to resolve the issue, potentially through a reverse stock split. Failure to comply could result in delisting, though the company can appeal such a decision.